Combined with UPLC-Triple-TOF/MS-based Plasma Lipidomics and Molecular Pharmacology Reveals the Mechanisms of Schisandrin Against Alzheimer's Disease

Overview

Journal Chin Med

Publisher Biomed Central

Specialty Biomedical Engineering

Date 2023 Feb 7

PMID 36747236

Authors

Tian-Tian Zhao

Ying Zhang

Cheng-Qin Zhang

Ya-Fei Chang

Mei-Rong Cui

Yue Sun

Wen-Qian Hao

Yu-Meng Yan

Shuo Gu

Yao Xie

Bin-Bin Wei

Affiliations

Soon will be listed here.

Abstract

Background: Alzheimer's disease (AD), a type of neurodegeneration disease, is characterized by Aβ deposition and tangles of nerve fibers. Schisandrin is one of the main components of Fructus Schisandrae Chinensis. Researches showed that schisandrin can improve the cognitive impairment and memory of AD mice, but the specific mechanism has not been fully elucidated.

Purpose: The purpose of this study is to investigate the possible mechanism of schisandrin in improving AD pathology.

Methods: The Morris water maze test was executed to detect spatial learning and memory. Ultra performance liquid chromatography-Triple time of flight mass spectrometry (UPLC-Triple-TOF/MS)-based plasma lipidomics was used to study the changes of plasma lipids. Moreover, we measured the levels of protein and mRNA expression of APOE and ABCA1 in the rat brains and in BV2 microglia.

Results: Our study found that schisandrin could improve learning and memory, and reduce Aβ deposition in AD rats. Furthermore, we found that schisandrin can improve plasma lipid metabolism disorders. Therefore, we hypothesized schisandrin might act via LXR and the docking results showed that schisandrin interacts with LXRβ. Further, we found schisandrin increased the protein and mRNA expression of LXR target genes APOE and ABCA1 in the brain of AD rats and in BV2 microglia.

Conclusion: Our study reveals the neuroprotective effect and mechanism of schisandrin improves AD pathology by activating LXR to produce APOE and ABCA1.

Citing Articles

Research Progress on Natural Plant Molecules in Regulating the Blood-Brain Barrier in Alzheimer's Disease.

Wu W, Huang J, Han P, Zhang J, Wang Y, Jin F Molecules. 2023; 28(22).

PMID: 38005352 PMC: 10674591. DOI: 10.3390/molecules28227631.

References

Wu C, Chen C, Lai C, Hung T, Lin C, Chao M . Treatment with TO901317, a synthetic liver X receptor agonist, reduces brain damage and attenuates neuroinflammation in experimental intracerebral hemorrhage. J Neuroinflammation. 2016; 13(1):62. PMC: 4788882. DOI: 10.1186/s12974-016-0524-8. View

Xu X, Xiao X, Yan Y, Zhang T . Activation of liver X receptors prevents emotional and cognitive dysfunction by suppressing microglial M1-polarization and restoring synaptic plasticity in the hippocampus of mice. Brain Behav Immun. 2021; 94:111-124. DOI: 10.1016/j.bbi.2021.02.026. View

Lefterov I, Bookout A, Wang Z, Staufenbiel M, Mangelsdorf D, Koldamova R . Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment. Mol Neurodegener. 2007; 2:20. PMC: 2214725. DOI: 10.1186/1750-1326-2-20. View

Schulman I . Liver X receptors link lipid metabolism and inflammation. FEBS Lett. 2017; 591(19):2978-2991. PMC: 5638683. DOI: 10.1002/1873-3468.12702. View

Yin Y, Wang Z . ApoE and Neurodegenerative Diseases in Aging. Adv Exp Med Biol. 2018; 1086:77-92. DOI: 10.1007/978-981-13-1117-8_5. View

Hu D, Cao Y, He R, Han N, Liu Z, Miao L . Schizandrin, an antioxidant lignan from Schisandra chinensis, ameliorates Aβ1-42-induced memory impairment in mice. Oxid Med Cell Longev. 2012; 2012:721721. PMC: 3399599. DOI: 10.1155/2012/721721. View

Wu W, He X, Xie S, Li B, Chen J, Qu Y . Protective effects of Huang-Lian-Jie-Du-Tang against A-induced memory deficits and oxidative stress in rats. J Int Med Res. 2020; 48(3):300060519893859. PMC: 7133406. DOI: 10.1177/0300060519893859. View

Sodhi R, Singh N . Liver X receptors: emerging therapeutic targets for Alzheimer's disease. Pharmacol Res. 2013; 72:45-51. DOI: 10.1016/j.phrs.2013.03.008. View

Whiley L, Sen A, Heaton J, Proitsi P, Garcia-Gomez D, Leung R . Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging. 2013; 35(2):271-8. PMC: 5866043. DOI: 10.1016/j.neurobiolaging.2013.08.001. View

10.

Paolo G, Kim T . Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci. 2011; 12(5):284-96. PMC: 3321383. DOI: 10.1038/nrn3012. View

11.

Deng J, Shen C, Wang Y, Zhang M, Li J, Xu Z . Nicotine exacerbates tau phosphorylation and cognitive impairment induced by amyloid-beta 25-35 in rats. Eur J Pharmacol. 2010; 637(1-3):83-8. DOI: 10.1016/j.ejphar.2010.03.029. View

12.

Farr S, Yamada K, Butterfield D, Abdul H, Xu L, Miller N . Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology. 2008; 149(5):2628-36. PMC: 2329289. DOI: 10.1210/en.2007-1722. View

13.

Qiu C, Kivipelto M, von Strauss E . Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009; 11(2):111-28. PMC: 3181909. View

14.

Lane C, Hardy J, Schott J . Alzheimer's disease. Eur J Neurol. 2017; 25(1):59-70. DOI: 10.1111/ene.13439. View

15.

Akyol S, Ugur Z, Yilmaz A, Ustun I, Gorti S, Oh K . Lipid Profiling of Alzheimer's Disease Brain Highlights Enrichment in Glycerol(phospho)lipid, and Sphingolipid Metabolism. Cells. 2021; 10(10). PMC: 8534054. DOI: 10.3390/cells10102591. View

16.

Kao Y, Ho P, Tu Y, Jou I, Tsai K . Lipids and Alzheimer's Disease. Int J Mol Sci. 2020; 21(4). PMC: 7073164. DOI: 10.3390/ijms21041505. View

17.

Lei C, Lin R, Wang J, Tao L, Fu X, Qiu Y . Amelioration of amyloid β-induced retinal inflammatory responses by a LXR agonist TO901317 is associated with inhibition of the NF-κB signaling and NLRP3 inflammasome. Neuroscience. 2017; 360:48-60. DOI: 10.1016/j.neuroscience.2017.07.053. View

18.

Wong M, Braidy N, Poljak A, Sachdev P . The application of lipidomics to biomarker research and pathomechanisms in Alzheimer's disease. Curr Opin Psychiatry. 2016; 30(2):136-144. DOI: 10.1097/YCO.0000000000000303. View

19.

Lanfranco M, Ng C, Rebeck G . ApoE Lipidation as a Therapeutic Target in Alzheimer's Disease. Int J Mol Sci. 2020; 21(17). PMC: 7503657. DOI: 10.3390/ijms21176336. View

20.

Wang B, Tontonoz P . Liver X receptors in lipid signalling and membrane homeostasis. Nat Rev Endocrinol. 2018; 14(8):452-463. PMC: 6433546. DOI: 10.1038/s41574-018-0037-x. View